QUICK SPARK: Amgen Stock Eyes Worst Day Since October 2000
In brief
Amgen’s stock plunged 9.8% after Novartis’ failed Lp(a) trial, shaking confidence in Amgen’s competing therapy.
ClearTape summarizes context in-app. For the full publisher article, use Read original source above.